Non-small Cell Lung Cancer Therapeutics Market Size, Share & Trends Analysis Report By Type (Squamous Cell Carcinoma), By Treatment (Chemotherapy), By Distribution Channel, By Region, And Segment Forecasts, 2024

Description

Non-small Cell Lung Cancer Therapeutics Market Growth & Trends:

The global non-small cell lung cancer therapeutics market size is expected to reach USD 43.89 billion by 2030, registering a CAGR of 12.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The non-small cell cancer therapeutics (NSCLC) market is anticipated to witness significant growth during the forecast period. This can be attributed to the high investment by market players in the research and development of lung cancer therapy, presence of a rich pipeline, and increasing penetration of drugs during the forecast period.

Introduction of several drugs in various geographical regions is likely to drive the market during the forecast period. For instance, in October 2016, the FDA granted Breakthrough Therapy Designation to Alecensa (alectinib), a drug developed by Genentech to treat ALK-positive NSCLC as a first-line treatment. The drug has been approved in the U.S., Japan, Canada, Hong Kong, South Korea, Kuwait, and Israel.

Presence of a strong pipeline of drugs for non-small cell lung cancer helps propel the market during the forecast period. Bristol-Myers Squibb Company, Orion Corporation, Merck KGaA, AstraZeneca, F. Hoffmann-La Roche Ltd, and Pfizer, Inc. have major molecules in the pipeline.

Non-small Cell Lung Cancer Therapeutics Market Report Highlights:

The adenocarcinoma segment dominated the market in 2023 with a share of 43.3% in 2023 due to increase in the population consuming tobacco and other products for smoking.
The targeted therapy segment dominated the market in 2023 with a share of 50.5% in 2023. The factors responsible for the market growth are the benefits of this therapy such as increased number of targeted therapeutics and low percentage of side effects during the treatment.
The hospital pharmacy segment dominated the market in 2023 with a share of 66.7% in 2023. This market growth was attributed to the increase in the number of hospitalized patients suffering from NSCLC.
North America dominated the non-small cell lung cancer therapeutics market with a market share of 35.4% in 2023. This growth was attributed to the presence of developed healthcare facilities and increased awareness regarding cancer treatments.

Product Code: GVR-1-68038-703-2

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Non-small cell lung cancer therapeutics market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. Non-small Cell Lung Cancer Therapeutics Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. Non-small Cell Lung Cancer Therapeutics Market: Type Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Non-small Cell Lung Cancer Therapeutics Market: Type Movement Analysis, 2023 & 2030 (USD Million)
4.3. Squamous Cell Carcinoma
- 4.3.1. Squamous Cell Carcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Large Cell Carcinoma
4.5. Large Cell Carcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Adenocarcinoma
- 4.6.1. Adenocarcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Others
- 4.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Non-small Cell Lung Cancer Therapeutics Market: Treatment Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Non-small Cell Lung Cancer Therapeutics Market: Treatment Movement Analysis, 2023 & 2030 (USD Million)
5.3. Chemotherapy
- 5.3.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Targeted Therapy
- 5.4.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Immunotherapy
- 5.5.1. Immunotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Non-small Cell Lung Cancer Therapeutics Market: Distribution Channel Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Non-small Cell Lung Cancer Therapeutics Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
6.3. Hospital Pharmacy
- 6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Drug Store and Retail Pharmacy
- 6.4.1. Drug Store and Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Online Pharmacy
- 6.5.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Non-small Cell Lung Cancer Therapeutics Market: Regional Estimates & Trend Analysis

7.1. Non-small Cell Lung Cancer Therapeutics Market Share, By Region, 2023 & 2030 (USD Million)
7.2. North America
- 7.2.1. North America Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.2. U.S.
  - 7.2.2.1. U.S. Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.3. Canada
  - 7.2.3.1. Canada Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.4. Mexico
  - 7.2.4.1. Mexico Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
- 7.3.1. Europe Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2. UK
  - 7.3.2.1. UK Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.3. Germany
  - 7.3.3.1. Germany Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.4. France
  - 7.3.4.1. France Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.5. Italy
  - 7.3.5.1. Italy Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.6. Spain
  - 7.3.6.1. Spain Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.7. Denmark
  - 7.3.7.1. Denmark Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.8. Sweden
  - 7.3.8.1. Sweden Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.9. Norway
  - 7.3.9.1. Norway Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
- 7.4.1. Asia Pacific Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. Japan
  - 7.4.2.1. Japan Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. China
  - 7.4.3.1. China Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. India
  - 7.4.4.1. India Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.5. Australia
  - 7.4.5.1. Australia Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.6. South Korea
  - 7.4.6.1. South Korea Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.7. Thailand
  - 7.4.7.1. Thailand Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
- 7.5.1. Latin America Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. Brazil
  - 7.5.2.1. Brazil Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Argentina
  - 7.5.3.1. Argentina Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
- 7.6.1. Middle East and Africa Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. South Africa
  - 7.6.2.1. South Africa Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. Saudi Arabia
  - 7.6.3.1. Saudi Arabia Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. UAE
  - 7.6.4.1. UAE Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. Kuwait
  - 7.6.5.1. Kuwait Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
- 8.4.1. F. Hoffmann-La Roche Ltd
  - 8.4.1.1. Participant's Overview
  - 8.4.1.2. Financial Performance
  - 8.4.1.3. Product Benchmarking
  - 8.4.1.4. Recent Developments/ Strategic Initiatives
- 8.4.2. Mylan N.V.
  - 8.4.2.1. Participant's Overview
  - 8.4.2.2. Financial Performance
  - 8.4.2.3. Product Benchmarking
  - 8.4.2.4. Recent Developments/ Strategic Initiatives
- 8.4.3. Teva Pharmaceutical Industries Ltd.
  - 8.4.3.1. Participant's Overview
  - 8.4.3.2. Financial Performance
  - 8.4.3.3. Product Benchmarking
  - 8.4.3.4. Recent Developments/ Strategic Initiatives
- 8.4.4. Sanofi
  - 8.4.4.1. Participant's Overview
  - 8.4.4.2. Financial Performance
  - 8.4.4.3. Product Benchmarking
  - 8.4.4.4. Recent Developments/ Strategic Initiatives
- 8.4.5. Pfizer Inc.
  - 8.4.5.1. Participant's Overview
  - 8.4.5.2. Financial Performance
  - 8.4.5.3. Product Benchmarking
  - 8.4.5.4. Recent Developments/ Strategic Initiatives
- 8.4.6. GSK plc
  - 8.4.6.1. Participant's Overview
  - 8.4.6.2. Financial Performance
  - 8.4.6.3. Product Benchmarking
  - 8.4.6.4. Recent Developments/ Strategic Initiatives
- 8.4.7. Novartis AG
  - 8.4.7.1. Participant's Overview
  - 8.4.7.2. Financial Performance
  - 8.4.7.3. Product Benchmarking
  - 8.4.7.4. Recent Developments/ Strategic Initiatives
- 8.4.8. Bayer AG
  - 8.4.8.1. Participant's Overview
  - 8.4.8.2. Financial Performance
  - 8.4.8.3. Product Benchmarking
  - 8.4.8.4. Recent Developments/ Strategic Initiatives
- 8.4.9. Eli Lilly and Company
  - 8.4.9.1. Participant's Overview
  - 8.4.9.2. Financial Performance
  - 8.4.9.3. Product Benchmarking
  - 8.4.9.4. Recent Developments/ Strategic Initiatives
- 8.4.10. Merck & Co., Inc
  - 8.4.10.1. Participant's Overview
  - 8.4.10.2. Financial Performance
  - 8.4.10.3. Product Benchmarking
  - 8.4.10.4. Recent Developments/ Strategic Initiatives

Non-small Cell Lung Cancer Therapeutics Market Size, Share & Trends Analysis Report By Type (Squamous Cell Carcinoma), By Treatment (Chemotherapy), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030